Get more information about HEMGENIX and hemophilia B.
Stay informed
Enroll your patients in support from HEMGENIX ConnectSM
Enroll now
Call 1-833-436-0021 Monday through Friday, 8 AM-8 PM ET.
The latest data reinforce the long-term efficacy and safety profile of HEMGENIX1
through 4 years post-administration
of HEMGENIX1
*Two patients experienced lack of efficacy. One patient had the highest NAb titer of 1:3212, and 1 patient received ~10% of the planned dose. One patient returned to factor IX prophylaxis at month 30 and their last factor IX activity levels were 3.6%. An additional patient required intermittent prophylaxis for approximately 20 weeks during months 7－18.
Box plot of factor IX activity (%) from one-stage (aPTT-based) assay over time (full analysis set)2
Click to enlarge
No clinically meaningful correlation was identified between a subject’s AAV5 NAb titer at baseline (up to a titer of 1:700) and their factor IX activity at Year 4 postdose.
aPTT, activated partial thromboplastin time; M, Month; W, Week.
†Baseline factor IX was imputed based on the subject’s historical hemophilia B severity documented on the Case Report Form. If the subject had documented severe factor IX deficiency (factor IX plasma level <1%), their baseline factor IX activity level was imputed as 1%. If the subject had documented moderately severe factor IX deficiency (factor IX plasma level ≥1% and ≤2%), their baseline factor IX activity level was imputed as 2%. Standard error was not provided at baseline.
Notes: Uncontaminated data from the central laboratory were used; “uncontaminated” meant that the blood sampling did not occur within 5 half-lives of exogenous factor IX use. Factor IX levels beginning with the Week 3 assessment were used in the analysis. Both the date and time of exogenous factor IX use (start) and blood sampling were considered in determining contamination. All efficacy data collected after liver transplants were excluded from the analysis. The lower and upper edges of the box correspond to the interquartile range, the 25th, and 75th percentile. The line at the middle of the box corresponds to the median. The whiskers (horizontal lines connected to vertical lines) show the lowest and highest observation within 1.5 times the interquartile range of the bottom and top of the box, respectively. The diamond is the arithmetic mean. Any points outside of the whiskers are plotted individually.
Click to enlarge
| TRAEs by MedDRA PT§ | Year 4 Postdose | |
|---|---|---|
| n (%) | No. of Events | |
| At least 1 TRAE¶ | 39 (72.2) | 96 |
| ALT increased | 10 (18.5) | 11 |
| Headache | 8 (14.8) | 9 |
| Influenza-like illness | 7 (13.0) | 8 |
| AST increased | 6 (11.1) | 7 |
| CPK increased | 4 (7.4) | 6 |
| Dizziness | 4 (7.4) | 4 |
| Fatigue | 4 (7.4) | 4 |
| Nausea | 4 (7.4) | 4 |
| Arthralgia | 3 (5.6) | 3 |
Click to enlarge
| TRAEs by MedDRA PT§ | Year 4 Postdose | |
|---|---|---|
| n (%) | No. of Events | |
| At least 1 TRAE¶ | 39 (72.2) | 96 |
| ALT increased | 10 (18.5) | 11 |
| Headache | 8 (14.8) | 9 |
| Influenza-like illness | 7 (13.0) | 8 |
| AST increased | 6 (11.1) | 7 |
| CPK increased | 4 (7.4) | 6 |
| Dizziness | 4 (7.4) | 4 |
| Fatigue | 4 (7.4) | 4 |
| Nausea | 4 (7.4) | 4 |
| Arthralgia | 3 (5.6) | 3 |
ABR, annualized bleeding rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; TRAE, treatment-related adverse event.
§MedDRA Version 26.0 was used for coding.
¶Related=Possibly related or related.
#Infusion-related reactions were defined as any AEs related to the investigation medical product administration procedure or unexpected reactions. They were any treatment-emergent adverse event occurring within 24 hours of infusion, qualifying for special notification, assessed as related or possibly related by the investigator and considered as an infusion-related reaction during the safety assessment. They were infusion-site reaction, hypersensitivity (eg, urticaria), facial flushing, itching, headache, dizziness, etc.
References: 1. Pipe SW, on behalf of the HOPE-B Investigators. The Phase 3 HOPE-B trial shows 4-year durability of sustained near-normal FIX activity, bleed protection and favourable safety in adults with severe or moderately severe haemophilia B. Presented at: 18th Annual Congress of the European Association for Haemophilia and Allied Disorders; February 4-7, 2025; Milan, Italy. 2. Data on File. Available from CSL Behring as DOF HGX-009.
Warning and Precautions
Infusion Reactions
Infusion reactions, including hypersensitivity reactions and anaphylaxis, may occur. Monitor during administration and for at least 3 hours after end of infusion. If symptoms occur, slow or interrupt administration. Re-start administration at a slower infusion once resolved.
Hepatotoxicity/Hepatocellular Carcinoma
Post-dose, monitor for elevated transaminase levels. Consider corticosteroid treatment should elevations occur. The integration of liver-targeting AAV vector DNA into the genome may carry the theoretical risk of hepatocellular carcinoma development. For patients with preexisting risk factors for hepatocellular carcinogenicity, perform regular (eg, annual) abdominal ultrasound and alpha-fetoprotein testing following administration.
Immune-mediated neutralization of the AAV5 vector capsid
Preexisting neutralizing anti-AAV antibodies may impede transgene expression at desired levels.
Monitoring Laboratory Tests
In addition to monitoring liver function, monitor for Factor IX activity and Factor IX inhibitors after administration.
Adverse Reactions
The most common adverse reactions (incidence ≥5%) were elevated ALT, headache, blood creatine kinase elevations, flu-like symptoms, infusion-related reactions, fatigue, nausea, malaise, and elevated AST.
Indication
HEMGENIX®, etranacogene dezaparvovec-drlb, is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:
HEMGENIX is for single use intravenous infusion only.
Contraindications: None.
Please see full prescribing information for HEMGENIX.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
